Effect of repeated normobaric hypoxia exposures during sleep on acute mountain sickness, exercise performance, and sleep during exposure to terrestrial altitude.
There is an expectation that repeated daily exposures to normobaric hypoxia (NH) will induce ventilatory acclimatization and lessen acute mountain sickness (AMS) and the exercise performance decrement during subsequent hypobaric hypoxia (HH) exposure. However, this notion has not been tested objectively. Healthy, unacclimatized sea-level (SL) residents slept for 7.5 h each night for 7 consecutive nights in hypoxia rooms under NH [n = 14, 24 ± 5 (SD) yr] or "sham" (n = 9, 25 ± 6 yr) conditions. The ambient percent O(2) for the NH group was progressively reduced by 0.3% [150 m equivalent (equiv)] each night from 16.2% (2,200 m equiv) on night 1 to 14.4% (3,100 m equiv) on night 7, while that for the ventilatory- and exercise-matched sham group remained at 20.9%. Beginning at 25 h after sham or NH treatment, all subjects ascended and lived for 5 days at HH (4,300 m). End-tidal Pco(2), O(2) saturation (Sa(O(2))), AMS, and heart rate were measured repeatedly during daytime rest, sleep, or exercise (11.3-km treadmill time trial). From pre- to posttreatment at SL, resting end-tidal Pco(2) decreased (P < 0.01) for the NH (from 39 ± 3 to 35 ± 3 mmHg), but not for the sham (from 39 ± 2 to 38 ± 3 mmHg), group. Throughout HH, only sleep Sa(O(2)) was higher (80 ± 1 vs. 76 ± 1%, P < 0.05) and only AMS upon awakening was lower (0.34 ± 0.12 vs. 0.83 ± 0.14, P < 0.02) in the NH than the sham group; no other between-group rest, sleep, or exercise differences were observed at HH. These results indicate that the ventilatory acclimatization induced by NH sleep was primarily expressed during HH sleep. Under HH conditions, the higher sleep Sa(O(2)) may have contributed to a lessening of AMS upon awakening but had no impact on AMS or exercise performance for the remainder of each day.
Thermal and Mountain Medicine Division, US Army Research Institute of Environmental Medicine, Kansas St., Natick, MA 01760, USA. Charles.fulco@us.army.mil
Charles S
CS
Fulco
Stephen R
SR
Muza
Beth A
BA
Beidleman
Robby
R
Demes
Janet E
JE
Staab
Juli E
JE
Jones
Allen
A
Cymerman
D000064:Acclimatization / Q000502:physiology*; D000328:Adult; D000531:Altitude; D000532:Altitude Sickness / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D001274:Atmospheric Pressure; D002245:Carbon Dioxide / Q000097:blood; D004921:Erythropoietin / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D000860:Hypoxia / Q000503:physiopathology*; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000502:physiology; D010313:Partial Pressure; D005082:Physical Exertion / Q000502:physiology; D011659:Pulmonary Gas Exchange / Q000502:physiology; D012123:Pulmonary Ventilation / Q000502:physiology; D012890:Sleep / Q000502:physiology*; D055815:Young Adult
C554270:EPO protein, human; D006454:Hemoglobins; D004921:Erythropoietin; D002245:Carbon Dioxide; D010100:Oxygen; D006854:Hydrocortisone; D009638:Norepinephrine